Company intelligence / Profile preview

Panaxia Labs Israel

Lod, Central District, Israelpanaxia.co.il ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Panaxia Labs Israel is Israel's largest and leading manufacturer of medical cannabis products, specializing in pharmaceutical-grade products such as sublingual tablets, oils, and vaporization extracts. The company operates under dual IMC-GMP and EU-GMP standards, holding EU-GMP certification for export to Europe. It offers over 30 products with clinical experience from tens of thousands of patients. Post-2020, Panaxia Labs Israel transitioned to a significant European export focus (Germany, France, Cyprus). As a subsidiary of Panaxia Global and part of the Segal Pharma Group, it leverages over 50 years of pharmaceutical expertise.

Therapeutic areas: PsychiatryNeurologyDermatologyOncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PANAXIR

Partnerships

NeuraxpharmRafa Laboratories

Beyond the preview

Go deeper on Panaxia Labs Israel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panaxia Labs Israel.